News

EZH2 is a histone methyltransferase (HMT), which will play a potentially oncogenic role in a number of cancers such as germinal centre (GC) non-Hodgkin lymphomas, INI1-deficient cancers such

The drug has also been designated an orphan drug by the US Food and Drug Administration (FDA) to treat pancreatic cancer and small-cell lung cancer. The company claims

Granted marketing authorization under the trade-name Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The marketing

The company’s ANDA product is a generic version of Pfizer and Tris Pharma’s Quillivant XR, which is a central nervous system (CNS) stimulant indicated to treat attention deficit

Currently, OPS202 is evaluated in Phase I/II clinical trials and is based on a new next generation antagonistic somatostatin analog with improved receptor binding to sst2. The company

As part of the deal, Aduro will receive a $30m up-front payment and is also eligible to receive significant development, regulatory and commercialization milestone payments up to a

As part of the development, Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, while Immune Design will provide its preclinical trivalent vaccine product candidate

Type 1 diabetics are unable to produce the insulin required to transport glucose (blood sugar) from the blood to the inside of cells where it is used as

Batu Biologics plans to utilize the licensed technology to enhance the potency of the antigen-specific immune response induced by the company’s novel ValloVax™ lung cancer vaccine. The company